Here, we learn how world leading supplier Bioquell devised a PRP for a Biopharmaceutical Production Facility ensuring high-level bio-decontamination in the event of contamination.
Christine Hancock, Founder and Director at C3 Collaborating for Health, discusses the ongoing issue of health inequality that COVID-19 has exposed, and how to ensure healthy lives for all.
The US is facing a fourth wave of COVID-19, as emergency healthcare workers across the country continue to face the virus and experience levels of burnout that can lead to PTSD.
New CDC guidelines suggest that surfaces are a "low-risk" for COVID transmission - cleaning surfaces with detergent or soap once a day should be enough to reduce possible virus levels.
According to a new study, by researchers at Danderyd Hospital and Karolinska Institutet in Sweden, 1 in 10 people still experience symptoms of COVID-19 8 months after infection.
Today (8 April) it was revealed that over 700,000 AstraZeneca doses manufactured in the UK are being sent to Australia - with a confirmed 300,000 vaccines in Sydney at the end of February.
New data from the REACT study finds that the prevalence of COVID is down by 60% in one month, but primary school children have the highest COVID infection levels.
The UK's medical authorities cleared continued use of AstraZeneca, but say that 18-29 year olds should take an alternative vaccine to AstraZeneca if possible.
A new study by Washington University School of Medicine suggests that breastfeeding mothers may pass protective COVID-19 antibodies to their babies through breast milk for at least 80 days following vaccination.
Open Access Government explores the health priorities of Stella Kyriakides, Commissioner for Health and Food Safety, asking if lessons learned from the ongoing COVID-19 pandemic can help to improve European healthcare?.
We spoke with Dr Matthew Duchars, CEO of the UK’s first dedicated Vaccines Manufacturing and Innovation Centre (VMIC), about their work not only to provide an integral response to COVID-19, but as a centre of excellence advancing the vaccine sector on a global scale.
A "human error" created a factory mixup for Johnson & Johnson in Baltimore, Maryland, damaging up to 15 million vaccine doses - but this does not impact doses that are ready for use.
Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.
